Topline results from the LiBBY trial (Life’s End Benefits of cannaBidiol and tetrahYdrocannabinol; NCT05644262) were presented in the Developing Topics session at the 2026 Alzheimer’s Association International Conference (AAIC) in London.
THC/CBD Combination Cuts Agitation in Hospice-Eligible Dementia: LiBBY Trial
- Post author:Randy Banks
- Post published:July 26, 2026
- Post category:News